Fig. 3From: Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trialRecommended dosing modifications for adverse events during oral azacitidine therapyBack to article page